Related references
Note: Only part of the references are listed.Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010
D. Pulte et al.
ANNALS OF ONCOLOGY (2010)
Which AML Subsets Benefit From Leukemic Cell Priming During Chemotherapy? Long-Term Analysis of the ALFA-9802 GM-CSF Study
Xavier Thomas et al.
CANCER (2010)
European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Hugo F. Fernandez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-tine therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
Stefan Faderl et al.
BLOOD (2008)
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
S Faderl et al.
BLOOD (2006)
Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older
A Bashey et al.
LEUKEMIA RESEARCH (2006)
Biochemical modulation of cytarabine triphosphate by clofarabine
T Cooper et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
S Faderl et al.
BLOOD (2005)
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients
GJ Ossenkoppele et al.
BLOOD (2004)
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
WK Hofmann et al.
ANNALS OF HEMATOLOGY (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
B Löwenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
De novo acute myeloid leukemia with multilineage dysplasia:: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG)
F Ferrara et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2002)
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia
J Braess et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Treatment of poor risk acute myeloid leukemia with fludarabine, cytarabine and G-CSF (FLAG regimen): A single center study
AM Carella et al.
LEUKEMIA & LYMPHOMA (2001)
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation
G Jackson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine
J Braess et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Share Paper
